OP Asset Management Ltd Makes New Investment in Hims & Hers Health, Inc. $HIMS

OP Asset Management Ltd bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the first quarter, HoldingsChannel.com reports. The firm bought 36,061 shares of the company’s stock, valued at approximately $749,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of HIMS. Vanguard Group Inc. boosted its stake in shares of Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after buying an additional 1,407,651 shares during the last quarter. Capital World Investors grew its holdings in shares of Hims & Hers Health by 1.2% in the third quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock worth $1,065,399,000 after acquiring an additional 223,892 shares during the period. Farallon Capital Management LLC increased its position in Hims & Hers Health by 30.8% during the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after acquiring an additional 2,533,271 shares during the last quarter. State Street Corp increased its position in Hims & Hers Health by 1.8% during the fourth quarter. State Street Corp now owns 7,305,525 shares of the company’s stock valued at $237,210,000 after acquiring an additional 132,311 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Hims & Hers Health by 12.4% in the fourth quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock valued at $183,485,000 after acquiring an additional 608,950 shares during the period. 63.52% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on HIMS. Barclays raised their target price on Hims & Hers Health from $29.00 to $39.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 17th. Jefferies Financial Group set a $24.50 price target on shares of Hims & Hers Health in a research report on Tuesday, May 12th. UBS Group set a $23.00 price objective on shares of Hims & Hers Health in a research note on Friday, May 22nd. TD Cowen dropped their price objective on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a report on Friday, March 27th. Finally, Bank of America reduced their target price on shares of Hims & Hers Health from $28.00 to $25.00 and set a “neutral” rating for the company in a report on Tuesday, May 26th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and a consensus target price of $29.37.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $34.54 on Wednesday. The stock has a 50-day simple moving average of $28.18 and a two-hundred day simple moving average of $26.31. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $70.43. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69. The firm has a market capitalization of $7.99 billion, a PE ratio of -383.76, a P/E/G ratio of 47.73 and a beta of 2.37.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. During the same quarter in the previous year, the company earned $0.20 EPS. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. Analysts forecast that Hims & Hers Health, Inc. will post 0.05 EPS for the current year.

Insider Buying and Selling

In other Hims & Hers Health news, insider Irene Becklund sold 4,490 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $141,435.00. Following the transaction, the insider owned 6,790 shares of the company’s stock, valued at $213,885. The trade was a 39.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Michael Chi sold 14,027 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total transaction of $441,850.50. Following the completion of the transaction, the chief operating officer owned 432,124 shares of the company’s stock, valued at approximately $13,611,906. The trade was a 3.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 163,973 shares of company stock worth $4,859,194 in the last ninety days. Corporate insiders own 11.76% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.